Phase III Study of Hemospan® for Treating Hypotension in Hip Arthroplasty

PHASE3CompletedINTERVENTIONAL
Enrollment

462

Participants

Timeline

Start Date

February 28, 2007

Primary Completion Date

March 31, 2008

Study Completion Date

April 30, 2008

Conditions
HypotensionIschemia
Interventions
DRUG

Hemospan (MP4OX)

250 mL unit dose, up to 500 mL total dose as needed at protocol-defined dosing triggers

DRUG

Voluven (HES 130/0.4)

250 mL unit dose, up to 500 mL total dose as needed at protocol-defined dosing triggers

Trial Locations (22)

Unknown

CHU Brugmann, Brussels

Z.O.L. Genk, Genk

Stedelijk Ziekenhuis Roeselare, Roeselare

Fakultni nemocnice Hradec Kralove, Hradec Králové

Fakultni nemocnice Motol, I. Ortopedicka klinika, Prague

Fakultni nemocnice Motol, II. Ortopedicka klinika, Prague

Fakultni nemocnice Na Bulovce, Prague

Medisch Spectrum Twente, Enschede

Tergooi Ziekenhuizen, locatie Hilversum, Hilversum

Sint Maartenskliniek, Nijmegen

UMC Erasmus, Rotterdam

Samodzielny Publiczny Szpital Kliniczny AM, Bialystok

SP Wojewódzki Szpital Chirurgii Urazowej, Piekary Śląskie

Wojewódzki Szpital Specjalistyczny nr 5, Sosnowiec

Instytut Reumatologii, Klinika Reumoortopedii, Warsaw

SK Dzieciątka Jezus, Warsaw

Länssjukhuset Gävle, Gävle

Kalmar Hospital, Kalmar

Lasarettet Motala, Motala

Danderyd Sjukhus, Stockholm

Söder Hospital, Stockholm

Uddevalla Sjukhus, Uddevalla

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Sangart

INDUSTRY